REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary
Home > Formulary : Adult > Recent Decisions > 2015 >

Decisions 20th January 2015

At the meeting on the 20th January 2015 the following decisions / changes to the formulary were agreed:


New Drug Requests



Umeclidinium (Incruse Ellipta®) (TLS Blue)

  • Approved for COPD maintenance.

Olodaterol (Striverdi Respimat®) (TLS Blue)

  • Approved for COPD maintenance.

Beclometasone and formoterol (Fostair® pMDI) (TLS Green)

  • Approved for COPD maintenance. Licence extension for use in COPD.  

Tiotropium (Respimat®) (TLS Amber specialist recommendation, no SCP)

  • Approved for use in asthma for those severe patients not controlled at step 4.

Progesterone (Cyclogest®) pessaries (TLS Red)

  • Approved for use in IVF patients and threatened pre-term labour.


More information required

Progesterone (Cyclogest®) pessaries

  • Not approved for use in recurrent miscarriage - await imminent results of the PROMISE trial.


Not approved

Tacrolimus mouthwash

  • Not approved for inclusion onto the formulary due to a lack of evidence in this cohort.  


Shared Care Protocols/TLS Change in Status


  • Agreed to change to amber (specialist recommendation, no SCP) to enable primary care prescribers to initiate if a specialist has recommended treatment.


  • To remain as amber 3 months as the NICE TA267 states that ‘Ivabradine should be initiated by a heart failure specialist with access to a multidisciplinary heart failure team. Dose titration and monitoring should be carried out by a heart failure specialist or in primary care by either a GP with a special interest in heart failure or a heart failure specialist nurse.’ 

Lisdexamfetamine (adults)

  • Agreed to change to amber 3 months once a SCP has been developed and approved.


Other decisions:

Indacaterol and glycopyrronium (Ultibro Breezhaler®)

  • Now available therefore can be added to the formulary for COPD as per December 2013 decision.